Following FDA approval, the MoMe ARC is expected to make its market debut in the fourth quarter of 2023. Credit: JHVEPhoto/Shutterstock

The virtual telemetry company, InfoBionic, has received US Food and Drug Administration (FDA) 510(k) clearance MoMe ARC solution.

The MoMe ARC incorporates a remote Electrocardiography (ECG) monitoring device and an initial Bluetooth diagnostic 6-lead sensor, to aid clinicians in their diagnosis of cardiac arrhythmias in patients with a need for cardiac monitoring.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It transmits ECG data in near-real-time, analysed by the MoMe software platform’s server-based algorithms, ensuring timely and accurate identification of crucial data for clinician review.

InfoBionic also claims the device is designed so patients can wear it discretely and comfortably during monitoring using standard electrodes.

Dave MacCutcheon, the Chief Operating Officer, said: “We’re thrilled to announce FDA 510(k) clearance to market the MoMe ARC solution, which supports our mission to create superior patient monitoring solutions for arrhythmia detection and virtual care and chronic disease management.”

See Also:

This device builds on its predecessor, the MoMe Kardia II, by introducing a decoupled 2-channel – 6-Lead Sensor, equipped with foundational technologies for compatibility with other Bluetooth-enabled health monitoring devices.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MacCutcheon added: “MoMe ARC is a solution that includes a 4-in-1 Gateway device that seamlessly transitions between 2-day in addition to Extended Holter tests, Event and MCT modes remotely, streamlining patient monitoring time and minimizing delays. In addition, MoMe® ARC leverages a comprehensive cloud-based proprietary platform to deliver on-demand, actionable data and analytics directly to the clinicians.”

Following FDA approval, the MoMe ARC is expected to make its market debut in the fourth quarter of 2023.